Acquisition by Raykov Rosty of 25000 shares of Fennec Pharmaceuticals at 2.69 subject to Rule 16b-3
FENC Stock | USD 6.19 0.02 0.32% |
About 57% of Fennec Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Fennec Pharmaceuticals suggests that many traders are alarmed. The current market sentiment, together with Fennec Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Fennec Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
Fennec |
Filed transaction by Fennec Pharmaceuticals Director. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at gurufocus.com
Fennec Pharmaceuticals Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Fennec Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Fennec Pharmaceuticals Fundamental Analysis
We analyze Fennec Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Fennec Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Fennec Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Outstanding
Shares Outstanding Comparative Analysis
Fennec Pharmaceuticals is currently under evaluation in shares outstanding category among its peers. Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Fennec Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Fennec Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Fennec Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Fennec Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Fennec Pharmaceuticals Related Equities
ANEB | Anebulo Pharmaceuticals | 26.26 | ||||
IKNA | Ikena Oncology | 7.74 | ||||
MOLN | Molecular Partners | 7.09 | ||||
OBIO | Orchestra BioMed | 2.56 | ||||
IRON | Disc Medicine | 2.23 | ||||
HRMY | Harmony Biosciences | 1.95 | ||||
AVTE | Aerovate Therapeutics | 1.19 | ||||
OLMA | Olema Pharmaceuticals | 0.32 | ||||
JANX | Janux Therapeutics | 1.07 | ||||
EWTX | Edgewise Therapeutics | 1.20 | ||||
LRMR | Larimar Therapeutics | 1.25 | ||||
MNOV | MediciNova | 2.36 | ||||
KROS | Keros Therapeutics | 2.39 | ||||
CSBR | Champions Oncology | 2.96 |
Complementary Tools for Fennec Stock analysis
When running Fennec Pharmaceuticals' price analysis, check to measure Fennec Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fennec Pharmaceuticals is operating at the current time. Most of Fennec Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Fennec Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fennec Pharmaceuticals' price. Additionally, you may evaluate how the addition of Fennec Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Stocks Directory Find actively traded stocks across global markets | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |